INCERT
Digital public agency INCERT GIE Luxembourg expands to the private sector with today’s launch of Keys&More, a hardware-agnostic enterprise key management system (KMS) designed for the complex deployment needs of manufacturers and industrial providers.
The KMS solution combines (1) a powerful platform for centralized management, (2) flexible deployment options and (3) strategic consulting services. Available via a cloud-based (KMSaaS), on-premises or hybrid option, Keys&More streamlines management of the entire key lifecycle: key preparation, creation, rotation, disabling, archiving and deletion.
Through one user-friendly platform, original equipment manufacturers (OEMs) oversee user management, digital signatures, encryption, decryption and beyond. This unified system helps them achieve compliance, boost operational efficiency, cut costs and apply cryptography best practices.
As a platform-independent solution, Keys&More functions with any cloud provider and multiple HSM and database vendors.
“Our value lies in our customizable deployment options. We know that the reality of cybersecurity can be messy: It’s common for larger organizations to find themselves with a patchwork of diverse processes and tools,” explains Benoit Poletti, Chief Executive Officer, INCERT. “Our solution turns that patchwork into one cohesive KMS. We adapt to the expertise and systems already present within a company, not the other way around. We’re making responsible key management as painless as possible, while unlocking new strategic opportunities.”
Keys&More expects to resonate with the automotive industry due to its (1) complex deployment needs, (2) growing dependence on connected devices and (3) industry regulations. The solution empowers organizations to safely leverage transformative trends, such as Vehicle-to-Everything, the Internet of Things and production line digitalization.
“This product is the result of INCERT’s historical skillset, our years of collaboration with a major automotive technology provider and our engagement with regulatory committees and R&D projects,” explains Sylvain Arts, Chief Business Officer, INCERT. “We really understand the challenges keeping OEMs from streamlining their key lifecycle management. But new regulations, especially in the automotive industry, mean that the adoption of a cohesive KMS solution cannot wait.”
“There is a strong business case for adopting a centralized KMS solution,” adds Benoit Poletti. “Crisis management, market positioning, compliance and auditing processes all improve with Keys&More. Having an efficient KMS in place makes it easier for organizations to scale, adapt and evolve—including, for example, transitioning to a post-quantum environment.”
“INCERT gave us the best value for money,” recalls INCERT’s major automotive industry client. “We could not live without them […]. Before they were an option, now they are a fundamental piece of the infrastructure. [… They were] very good at getting us everything we needed.”
ABOUT INCERT
INCERT was launched by the Government of Luxembourg in 2012 as a public digital services partner focused on critical IT infrastructure & verification of digital signatures. It soon began consulting foreign governments on the topics of public key infrastructure, identity management, standards & cybersecurity. Offering an entire ecosystem of services & solutions, INCERT’s public & private sector projects span the globe. With over a decade’s worth of insight, INCERT has developed its own unified KMS solution: Keys&More.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412187710/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
